Seres Therapeutics
MCRB
113 hedge funds and large institutions have $2.42B invested in Seres Therapeutics in 2020 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 40 increasing their positions, 30 reducing their positions, and 17 closing their positions.
607% more capital invested
Capital invested by funds: $342M → $2.42B (+$2.08B)
331% more call options, than puts
Call options by funds: $83.3M | Put options by funds: $19.3M
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 30
22% more funds holding
Funds holding: 93 → 113 (+20)
0.05% less ownership
Funds ownership: 4.96% → 4.91% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$79M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$51.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$31.8M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$29.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$31.1M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$31.1M |
| 3 |
Renaissance Technologies
New York
|
-$16.9M |
| 4 |
JP Morgan Chase
New York
|
-$12.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$5.27M |
MCRB Hedge Fund Activity: Q3 2020 in Review
113 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2020, worth a combined $2.42B — up 607% from $342M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MCRB positions and 17 closed out — a net gain of 20 holders — while 40 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $82.7M. The largest seller was Nikko Asset Management Americas, cutting an estimated $31.1M.
- 113 institutional investors held Seres Therapeutics (MCRB) as of Q3 2020, up from 93 in Q2 2020.
- Funds reported $2.42B of Seres Therapeutics stock for Q3 2020, up 607% quarter-over-quarter.
- 37 funds opened new Seres Therapeutics positions in Q3 2020 and 17 closed out, a net change of +20 holders.
- The largest Seres Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $82.7M added.
- The largest Seres Therapeutics seller in Q3 2020 was Nikko Asset Management Americas, an estimated $31.1M sold.
Based on aggregated 13F filings for Q3 2020.